Efficacy of CalliSpheres drug-loaded microsphere embolization in the treatment of primary massive liver cancer, and its effects on tumor markers and liver function

ObjectiveTo investigate the effects of CalliSpheres drug-loaded microsphere embolization in the treatment of primary massive liver cancer, and its effects on tumor markers and liver function.

MethodsEighty patients with primary massive liver cancer were divided into the control group and observation group according to the random number table method(40 cases in each group).The control group was treated with iodized oil transcatheter arterial chemoembolization, and the observation group was treated with CalliSpheres drug-loaded microsphere transcatheter arterial chemoembolization.The clinical effects, postoperative complications, and serum tumor markersincluding carbohydrate antigen 199(CA199), α-fetoprotein(AFP) and E-cadherin(EC), liver function indexincluding aspartate aminotransferase(AST), alanine aminotransferase(ALT), total bilirubin(TBIL) and albumin(Alb) levels between two groups after 1 and 3 months of operation were compared.The 1-year survival rate was compared between two groups.

ResultsThe disease remission rate and disease control rate(57.50% and 82.50%) in observation group were higher than those in control group after 3 months of operation(30.00% and 60.00%) (P < 0.05).The serum levels of CA199, AFP and EC in observation group after 1 and 3 months of operation were lower than those in control group(P < 0.01).After 3 months of operation, the serum levels of AST, ALT, TBIL in observation group were lower than those in control group(P < 0.01), and the level of Alb in observation group was higher than that in control group(P < 0.01).The incidence rate of fever and CINV grade in observation group were lower than those in control group(P < 0.05 and P < 0.01).The 1-year survival rate in observation group(73.68%) was higher than that in control group(51.35%)(P < 0.05).

ConclusionsThe CalliSpheres drug-loaded microsphere embolization in the treatment of primary massive liver cancer can further improve the therapeutic effects, has less impact on the liver function, and can effectively reduce the incidence rate of adverse reactions and improve the 1-year survival rate of patients.